(Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | (Q1)Sep 30, 2022 | (FY)Jun 30, 2022 | (Q4)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 23.55%-1.66M | -23.09%-2.64M | -93.41%-1.88M | -70.00%-8.58M | -210.68%-3.29M | -0.87%-2.17M | -80.17%-2.14M | -50.64%-974.1K | 3.54%-5.05M | 55.88%-1.06M |
Net income from continuing operations | 21.88%-1.75M | -9.18%-2.93M | -77.71%-1.91M | -92.81%-9.8M | -164.64%-3.8M | -20.77%-2.24M | -180.43%-2.68M | -29.15%-1.08M | 14.79%-5.08M | 21.32%-1.44M |
Operating gains losses | -517.97%-8.57K | -61.60%22.39K | 103.46%9.58K | 43.91%-192.97K | 123.20%27.28K | 97.08%-1.39K | 19,274.01%58.29K | -55.06%-277.15K | -148.62%-344.05K | -1,132.17%-117.61K |
Depreciation and amortization | -18.20%14.88K | -10.07%14.88K | -10.03%14.88K | -28.63%69.05K | -7.36%17.78K | -31.48%18.19K | -37.68%16.54K | -32.41%16.54K | -8.93%96.75K | -29.84%19.2K |
Asset impairment expenditure | ---- | ---- | ---- | --515.54K | --495.37K | ---- | ---- | ---- | --0 | --0 |
Unrealized gains and losses of investment securities | -95.00%5.19K | -120.00%-20.76K | -76.67%72.65K | -22.83%570.79K | -81.54%51.89K | -54.73%103.78K | 216.87%103.78K | 58.43%311.34K | 394.49%739.69K | 114.85%281.16K |
Remuneration paid in stock | 20.31%181.42K | -1.22%551.4K | 9.47%99.75K | 65.02%954.59K | 24.82%154.49K | 121.44%150.79K | 227.08%558.19K | -57.80%91.13K | 2,327.65%578.48K | 649.54%123.77K |
Other non cashItems | 43.81%-50.73K | -58.77%-233.64K | 1.99%-160.69K | -22.05%-595.91K | -87.73%-194.53K | 3.61%-90.27K | -32.25%-147.15K | 8.75%-163.96K | 12.48%-488.24K | 79.85%-103.62K |
Change In working capital | 61.49%-49.86K | 11.67%-47.14K | -106.52%-8.09K | 80.60%-106.75K | -131.48%-47.94K | 70.58%-129.45K | 85.60%-53.36K | 14.80%124.01K | -293.32%-550.25K | 148.35%152.31K |
-Change in receivables | -9.39%-24.38K | 776.09%104.9K | 336.55%37.62K | 73.28%-33.75K | 117.15%19.96K | -12,930.41%-22.28K | 90.52%-15.52K | -110.33%-15.91K | -37.76%-126.32K | -41.09%-116.38K |
-Change in payables and accrued expense | 87.43%-13.47K | -350.21%-170.4K | -171.35%-52.74K | 163.53%269.31K | 1,711.72%340.41K | 32.70%-107.17K | -121.50%-37.85K | 116.09%73.92K | -212.65%-423.93K | 109.75%18.79K |
-Change in other working capital | ---12.01K | --18.37K | -89.34%7.03K | ---342.31K | ---408.3K | --0 | --0 | -84.05%65.99K | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 23.55%-1.66M | -23.09%-2.64M | -93.41%-1.88M | -70.00%-8.58M | -204.98%-3.29M | -2.68%-2.17M | -77.48%-2.14M | -50.64%-974.1K | 3.54%-5.05M | 55.06%-1.08M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 191.09%64.88K | 10.51%153.71K | -33.36%103.58K | 7.35%514.64K | 150.08%197.83K | -84.83%22.29K | -45.46%139.09K | 9,396.47%155.44K | -93.46%479.38K | -83.28%79.11K |
Net PPE purchase and sale | 48.94%-39.32K | 60.64%-4.08K | ---8.67K | -90.30%-87.38K | ---1 | ---77.01K | 75.09%-10.37K | --0 | 68.82%-45.92K | --0 |
Interest received (cash flow from investment activities) | 4.94%104.2K | 5.57%157.79K | -27.78%112.26K | 14.60%602.02K | 150.08%197.83K | -32.43%99.3K | -49.62%149.46K | 5,855.44%155.44K | -25.33%525.3K | -85.39%79.11K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 191.09%64.88K | 10.51%153.71K | -33.36%103.58K | 7.35%514.64K | 150.08%197.83K | -84.83%22.29K | -45.46%139.09K | 9,396.47%155.44K | -93.46%479.38K | -83.28%79.11K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -136.05%-12.68K | -100.37%-10.56K | -38.08%-11.58K | 11,211.60%10.31M | 63,101.21%7.39M | 260.33%35.19K | 10,673.25%2.89M | 73.61%-8.38K | 53.95%-92.74K | 77.67%-11.73K |
Net issuance payments of debt | -8.08%-12.68K | -8.11%-12.68K | 1.35%-11.58K | 35.68%-46.46K | 4.07%-11.26K | 42.85%-11.74K | 42.87%-11.73K | 39.60%-11.73K | 4.31%-72.23K | 37.82%-11.73K |
Net common stock issuance | --0 | --0 | --0 | 52,696.42%10.42M | 38,156.64%7.54M | --0 | 42,878.71%2.89M | -10.62%-13.65K | 84.09%-19.81K | 38.50%-19.81K |
Proceeds from stock option exercised by employees | --0 | -50.00%2.13K | --0 | --281.35K | --213.18K | --46.92K | --4.25K | --17K | --0 | --0 |
Net other financing activities | ---- | ---- | ---- | -49,405.25%-349.01K | ---- | ---- | ---- | ---- | 51.51%-705 | --19.81K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -136.05%-12.68K | -100.37%-10.56K | -38.08%-11.58K | 11,211.60%10.31M | 63,101.21%7.39M | 271.34%35.19K | 10,153.98%2.89M | 73.61%-8.38K | 53.95%-92.74K | 77.67%-11.73K |
Net cash flow | ||||||||||
Beginning cash position | -36.93%3.75M | 22.97%6.3M | 42.56%8.12M | -43.15%5.7M | -41.79%3.84M | -30.29%5.95M | -46.14%5.13M | -43.15%5.7M | 12.79%10.02M | -45.06%6.6M |
Current changes in cash | 23.94%-1.61M | -383.12%-2.5M | -116.68%-1.79M | 147.99%2.24M | 524.26%4.3M | -6.32%-2.11M | 189.80%881.59K | -21.61%-827.04K | -346.22%-4.66M | 48.92%-1.01M |
Effect of exchange rate changes | 839.74%27.62K | 3.63%-54.61K | -110.97%-27.95K | -44.30%187.77K | -111.91%-13.35K | -94.12%2.94K | -4,865.52%-56.66K | 46.58%254.84K | 144.56%337.13K | 2,345.03%112.12K |
End cash Position | -43.41%2.17M | -36.93%3.75M | 22.97%6.3M | 42.56%8.12M | 42.56%8.12M | -41.79%3.84M | -30.29%5.95M | -46.14%5.13M | -43.15%5.7M | -43.15%5.7M |
Free cash from | 24.42%-1.7M | -22.69%-2.64M | -94.30%-1.89M | -70.18%-8.67M | -204.98%-3.29M | -6.32%-2.25M | -72.40%-2.15M | -49.65%-974.1K | 5.33%-5.09M | 56.23%-1.08M |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.